https://www.selleckchem.com/products/gdc-0994.html
DT56a is a possible alternative for the treatment of acute climacteric syndrome. In the Central European population, the efficacy of a daily dose of 644 mg corresponds with the effects observed in the Mediterranean population (Tab. 2, Fig. 3, Ref. 21). Text in PDF www.elis.skKEY WORDS DT56a, climacteric syndrome, menopause, non-hormonal treatment.We report a catalytic cross-coupling process between aryl (pseudo)halides and boron-based acyl anion equivalents. This mode of acylboronate reactivity represents polarity reversal, which is su
Like
Comment
Share
